OncoMed Pharmaceuticals, Inc. Presents New Data in Six Anti-Cancer Stem Cell Programs at American Association for Cancer Research

Published: Apr 10, 2013

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed’s pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

Back to news